ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

TRML Tourmaline Bio Inc

15.86
0.31 (1.99%)
After Hours
Last Updated: 23:56:07
Delayed by 15 minutes
Share Name Share Symbol Market Type
Tourmaline Bio Inc NASDAQ:TRML NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.31 1.99% 15.86 13.57 16.74 15.525 14.925 15.50 223,881 23:56:07

Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

01/02/2024 1:00pm

GlobeNewswire Inc.


Tourmaline Bio (NASDAQ:TRML)
Historical Stock Chart


From Dec 2023 to Jun 2024

Click Here for more Tourmaline Bio Charts.

Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, CEO, will present at the in the following investor conference:

Guggenheim Healthcare Talks | 6th Annual Biotechnology ConferenceFireside chat February 7, 2024 at 11:00am ET

A live webcast and replay will be under "Events and Presentations" in the News & Investors section of the Tourmaline Bio website at https://ir.tourmalinebio.com.

About Tourmaline Bio, Inc. Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases.

About TOUR006TOUR006 is a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class potential and differentiated properties including a naturally long half-life, low immunogenicity, and high binding affinity to IL-6. To date, TOUR006 has been studied in 448 participants, including patients with autoimmune disorders, across six clinical trials. Tourmaline is developing TOUR006 in TED and ASCVD as its first two indications, with additional diseases under consideration.

Contact:

Meru AdvisorsLee M. Sternlstern@meruadvisors.com

1 Year Tourmaline Bio Chart

1 Year Tourmaline Bio Chart

1 Month Tourmaline Bio Chart

1 Month Tourmaline Bio Chart

Your Recent History

Delayed Upgrade Clock